Infliximab - Janssen Biotech

Drug Profile

Infliximab - Janssen Biotech

Alternative Names: cA2; CenTNF; Remicade; TA-650

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Centocor; Janssen Biotech; Merck & Co; Mitsubishi Tanabe Pharma Corporation; National Jewish Medical and Research Center; Xian-Janssen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Antiulcers
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucocutaneous lymph node syndrome; Crohn's disease; Juvenile rheumatoid arthritis; Ankylosing spondylitis; Behcet's syndrome; Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Mucocutaneous lymph node syndrome; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Discontinued Berylliosis; Hepatitis C; Pyoderma

Most Recent Events

  • 13 Jul 2018 Janssen Korea completes the phase III BEGIN trial in Behcet's syndrome in South Korea (IV) (NCT02505568)
  • 20 Sep 2017 Pfizer initiates litigation against Johnson and Johnson to allow competition for biologics and expand options for patients in USA
  • 18 May 2017 Mitsubishi Tanabe Pharma receives an approval for partial change in administration/dosage for Crohn's disease in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top